MHRA-100372-PIP01-21-M01 (update)

Key Facts

Active Substance
Active Substance:
  • concizumab
Invented Name
  • Alhemo
  • Alhemo
PIP Number MHRA-100372-PIP01-21-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for injection in pre-filled pen
Therapeutic area
Therapeutic area:
  • Haematology-Hemostaseology
Conditions / Indications
  • Treatment of congenital haemophilia A
  • Treatment of congenital haemophilia B
Route(s) of administration
Route(s) of administration:
  • Subcutaneous use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):concizumab.pdf
Published Date 30/04/2024